SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the t:slim®, t:slim G4™ and t:flex® Insulin Pumps, today
announced the appointment of Henry Anhalt, DO, FACOP, FACE as an
independent member of its board of directors. Dr. Anhalt is a practicing
pediatric endocrinologist and chief medical officer of T1D Exchange, a
nonprofit organization fostering collaboration among patients,
physicians, researchers and industry to speed discovery of better
therapies for type 1 diabetes.
"Henry is a renowned, patient-centric physician whose passion for
helping people with diabetes aligns with our Company's mission, and we
welcome him to our Board," said Kim Blickenstaff, president and CEO,
Tandem Diabetes Care. "His breadth of clinical and industry experience
in diabetes care, and his deep understanding of automated insulin
delivery, brings tremendous value to our Company as we advance our
product development efforts and grow our business."
Prior to his current appointment at T1D Exchange, Dr. Anhalt held
numerous executive positions in the medical device and biopharmaceutical
industries. He was Senior Medical Director in Medical Diabetes at Sanofi
North America and was responsible for developing and executing the North
American Medical affairs strategy for Toujeo, a long-acting basal
insulin. Prior to that he was the Chief Medical Officer and Medical
Director of the Artificial Pancreas program at Animas, Inc. a Johnson
and Johnson Company.
Dr. Anhalt has had a long academic career during which he led the
pediatric endocrinology fellowship training program at the State
University of New York in Brooklyn. He has published more than 30
peer-reviewed papers, four textbook chapters, and dozens of clinical
abstracts. Dr. Anhalt has held senior leadership positions in many
professional organizations and currently serves as chair of the Hormone
Health Network of the Endocrine Society. He received his B.A. from
Yeshiva University, a D.O. from the New York College of Osteopathic
Medicine and completed his pediatric endocrinology fellowship at the
Lucille Salter Packard Children's Hospital at Stanford University.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim® Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first CGM-enabled
pump with touch-screen simplicity. Tandem is based in San Diego,
California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslim,
#tslimG4, #tflex, #tconnect, and $TNDM.
Follow Tandem Diabetes Care
on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/TandemDiabetes.
t:slim, t:flex and Tandem Diabetes Care are registered trademarks, and
t:slim G4 is a trademark of Tandem Diabetes Care, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160314006257/en/
for Tandem Diabetes Care®, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care®, Inc.
News Provided by Acquire Media
